Literature DB >> 21039762

Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Jürgen B Bulitta1, Martina Kinzig, Verena Jakob, Ulrike Holzgrabe, Fritz Sörgel, Nicholas H G Holford.   

Abstract

AIMS: (i) To describe the first-order and mixed-order elimination pathways of piperacillin, (ii) to determine the between occasion variability (BOV) of pharmacokinetic parameters and (iii) to propose optimized dosage regimens.
METHODS: We performed a five-period replicate dose study in four healthy volunteers. Each subject received 4g piperacillin as a single 5min intravenous infusion in each study period. Drug analysis was performed by HPLC. We used NONMEM and S-ADAPT for population pharmacokinetic analysis and Monte Carlo simulation to predict the probability of target attainment (PTA) with a target time of non-protein bound concentration above MIC >50% of the dosing interval.
RESULTS: A model with first-order nonrenal elimination and parallel first-order and mixed-order renal elimination had the best predictive performance. For a 70kg subject we estimated 4.40lh(-1) for nonrenal clearance, 5.70lh(-1) for first-order renal clearance, 170mgh(-1) for V(max) , and 49.7mgl(-1) for K(m) for the mixed-order renal elimination. The BOV was 39% for V(max) , 117% for K(m) , and 8.5% for total clearance. A 30min infusion of 4g every 6h achieved robust (≥90%) PTAs for MICs ≤12mgl(-1) . As an alternative mode of administration, a 5h infusion of 6g every 8h achieved robust PTAs for MICs ≤48mgl(-1) .
CONCLUSIONS: Part of the renal elimination of piperacillin is saturable at clinically used doses. The BOV of total clearance and volume of distribution were low. Prolonged infusions achieved better PTAs compared with shorter infusions at similar daily doses. This benefit was most pronounced for MICs between 12 and 48mgl(-1) .
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039762      PMCID: PMC2997308          DOI: 10.1111/j.1365-2125.2010.03750.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  68 in total

1.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.

Authors:  J W Mouton; M F Michel
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

Review 4.  Pharmacokinetic characteristics of piperacillin/tazobactam.

Authors:  F Sörgel; M Kinzig
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

5.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 6.  Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?

Authors:  Jason A Roberts; Jeffrey Lipman; Stijn Blot; Jordi Rello
Journal:  Curr Opin Crit Care       Date:  2008-08       Impact factor: 3.687

Review 7.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

8.  Implications of intraindividual variability in bioavailability studies of furosemide.

Authors:  A Grahnén; M Hammarlund; T Lundqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Overview of acylureidopenicillin pharmacokinetics.

Authors:  T Bergan
Journal:  Scand J Infect Dis Suppl       Date:  1981

10.  Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect.

Authors:  D L Stevens; S Yan; A E Bryant
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

View more
  11 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

Review 2.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

3.  Population pharmacokinetic analysis of piperacillin in burn patients.

Authors:  Sangil Jeon; Seunghoon Han; Jongtae Lee; Taegon Hong; Jeongki Paek; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

4.  Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.

Authors:  Fekade Bruck Sime; Uwe Hahn; Morgyn S Warner; Ing Soo Tiong; Michael S Roberts; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Authors:  Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker
Journal:  Antibiotics (Basel)       Date:  2022-03-24

6.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.

Authors:  Cornelia B Landersdorfer; Neang S Ly; Hongmei Xu; Brian T Tsuji; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

8.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Authors:  T W Felton; W W Hope; B M Lomaestro; J M Butterfield; A L Kwa; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 10.  Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Stefanie K Drescher; Antonio Oliver; Arnold Louie; Bartolome Moya; Xun Tao; Mathias Wittau; Brian T Tsuji; Alexandre P Zavascki; Beom Soo Shin; George L Drusano; Fritz Sörgel; Cornelia B Landersdorfer
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.